Nektar Therapeutics Repayments of Senior Debt
Nektar Therapeutics (NKTR) reported Repayments of Senior Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfSeniorDebt · last filed 2023-02-28
- Nektar Therapeutics repayments of senior debt for the quarter ending 2021-12-31 was $0.00.
- Nektar Therapeutics repayments of senior debt for the quarter ending 2021-09-30 was $0.00.
- Nektar Therapeutics repayments of senior debt for the quarter ending 2020-12-31 was $0.00.
- Nektar Therapeutics repayments of senior debt for the quarter ending 2020-09-30 was $0.00.
- Nektar Therapeutics repayments of senior debt for fiscal 2022 was $0.00.
- Nektar Therapeutics repayments of senior debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Nektar Therapeutics repayments of senior debt for fiscal 2020 was $250.00M.
- Nektar Therapeutics repayments of senior debt for fiscal 2019 was $0.00.
| Period end | Repayments of Senior Debt 3 month | Repayments of Senior Debt 6 month | Repayments of Senior Debt 9 month | Repayments of Senior Debt 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $250.00M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $250.00M 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | $250.00M 10-Q · filed 2021-08-06 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 10-K · filed 2022-03-01 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-07 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-26 | |||
| 2017-12-31 | $0.00 10-K · filed 2018-03-01 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-03-01 | |||
| 2015-12-31 | $125.00M 10-K · filed 2018-03-01 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-01 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |